title: Activation of alpha(2)-receptors in the rostral ventrolateral medulla evokes natriuresis by a renal nerve mechanism.
abstract: The contribution of alpha(2)-receptor mechanisms in the rostral ventrolateral medulla (RVLM) in mediating the enhanced renal excretory responses evoked by the intravenous infusion of the alpha(2)-receptor agonist xylazine was examined in ketamine-anesthetized rats. In ketamine-anesthetized rats, the bilateral microinjection of the alpha(2)-receptor antagonist yohimbine into the RVLM significantly reduced the enhanced levels of urine flow rate (V) and urinary sodium excretion (UNaV) produced by xylazine. In contrast, microinjection of yohimbine into the RVLM of chronically bilaterally renal-denervated rats significantly reduced the xylazine-evoked diuretic, but not natriuretic, response. In separate ketamine-anesthetized rats, intravenous xylazine infusion produced a near complete inhibition of renal sympathetic nerve activity (RSNA). The subsequent microinjection of yohimbine into the RVLM reversed this neural response and concurrently decreased V and UNaV. Together, these results indicate that during intravenous infusion, xylazine activates alpha(2)-receptor mechanisms in the RVLM to selectively promote urinary sodium excretion by a renal nerve-dependent pathway. In contrast, activation of alpha(2)-receptor in the RVLM affects the renal handling of water by a pathway independent of the renal nerves. This latter pathway may involve an interaction with other brain regions involved in antidiuretic hormone release (e.g., paraventricular nucleus of the hypothalamus).
authors.affiliation: Department of Physiological Sciences, Medical Center Federal University of Espirito Santo, Vitoria, Brazil 29040 - 090.
authors.forename: R G
authors.initials: RG
authors.lastname: Menegaz
authors.forename: D R
authors.initials: DR
authors.lastname: Kapusta
authors.forename: H
authors.initials: H
authors.lastname: Mauad
authors.forename: A
authors.initials: A
authors.lastname: de Melo Cabral
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000778:Anesthetics, Dissociative; D000818:Animals; D007649:Ketamine; D007668:Kidney / Q000294:innervation / Q000502:physiology*; D008297:Male; D008526:Medulla Oblongata / Q000187:drug effects / Q000378:metabolism*; D008845:Microinjections; D009318:Natriuresis / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D018341:Receptors, Adrenergic, alpha-2 / Q000378:metabolism*; D012964:Sodium / Q000652:urine; D013564:Sympathetic Nervous System / Q000502:physiology*; D014556:Urine; D014991:Xylazine / Q000494:pharmacology; D015016:Yohimbine / Q000494:pharmacology
chemical_list: D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D000778:Anesthetics, Dissociative; D018341:Receptors, Adrenergic, alpha-2; D014991:Xylazine; D015016:Yohimbine; D007649:Ketamine; D012964:Sodium